Metabolic Syndrome and Nonalcoholic Fatty Liver Disease

1. Yki-Jarvinen. H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. LancetDiabetes Endocrinol 2014; 2(11): 901–1010.1016/S2213-8587(14)70032-4Search in Google Scholar

2. Lonardo A, Ballestri S, Marchesini G et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig LiverDis 2015; 47: 181–90.10.1016/j.dld.2014.09.020Search in Google Scholar

3. Fukuda T, Hamaguchi M, Kojima T et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275–83.10.1111/liv.1291226176710Open DOISearch in Google Scholar

4. Matteoni C, Younossi Z, Gramlich T et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–19.10.1016/S0016-5085(99)70506-8Search in Google Scholar

5. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.10.1002/hep.2576222488764Search in Google Scholar

6. Donhoffer H. Quantitative estimation of lipids in needle biopsy sized specimens of cadaver liver. Acta Med Acad Sci Hung 1974; 31: 47–49.Search in Google Scholar

7. Hoyumpa AM Jr, Greene HL, Dunn GD, Schenker S. Fatty liver: Biochemical and clinical considerations. Dig Dis Sci 1975; 20: 1142–70.10.1007/BF010707581200009Search in Google Scholar

8. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134: 1369–75.10.1053/j.gastro.2008.01.075262939118355813Search in Google Scholar

9. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol 2010; 16: 5286–96.10.3748/wjg.v16.i42.5286298067721072891Open DOISearch in Google Scholar

10. Bedossa P, Poitou C, Veyrie N et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751–9.2270739510.1002/hep.2588922707395Search in Google Scholar

11. Flegal KM, Carroll MD, Kit BK et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307(5): 491-7.10.1001/jama.2012.3922253363Search in Google Scholar

12. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr PharmDes 2010; 16: 1941-51.10.2174/138161210791208875Search in Google Scholar

13. Gaggini M, Morelli M, Buzzigoli E et al. Non-alcoholic fatty liver disease (NAFLD and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544-60.10.3390/nu5051544Search in Google Scholar

14. Kotronen A, Westerbacka J, Bergholm R et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.10.1210/jc.2007-0482Open DOISearch in Google Scholar

15. Uchil D, Pipalia D, Chawla M et al. Non-alcoholic fatty liver disease (NAFLD) – the hepatic component of metabolic syndrome. J Assoc Physicians India 2009; 57: 201-4.Search in Google Scholar

16. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-510.1161/CIRCULATIONAHA.109.192644Search in Google Scholar

17. Williamson RM, Price JF, Glancy S et al. Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139-44.10.2337/dc10-2229Search in Google Scholar

18. DaiW. : Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A metaanalysis, Medicine (Baltimore) 2017; 96(39)10.1097/MD.0000000000008179Search in Google Scholar

19. Bellentani, S.; Tiribelli, C.: Epidemiology and risk factors for fatty liver. In: Leuschner U, James OFW, Dancyguer H (eds.). Steatohepatitis (NASH and ASH), Kluwer Academic Publishers:Dordrecht 2001; 3-10Search in Google Scholar

20. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274–8510.1111/j.1365-2036.2011.04724.xSearch in Google Scholar

21. Donahue RP, Abbott RD, Bloom E et al. Central obesity and coronary heart disease in men. Lancet 1987; 1: 821–4.10.1016/S0140-6736(87)91605-9Search in Google Scholar

22. Baldridge AD, Perez-Atayde AR,Graeme-Cook F et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995, 127: 700-4.10.1016/S0022-3476(95)70156-7Search in Google Scholar

23. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014; 20: 9072-89.Search in Google Scholar

24. Leite NC, Villela-Nogueira CA, Cardoso CR et al. Nonalcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20: 8377-92.10.3748/wjg.v20.i26.8377409369125024596Search in Google Scholar

25. Leite NC, Villela-Nogueira CA, Pannain VL el al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-6.10.1111/j.1478-3231.2011.02482.x21457442Open DOISearch in Google Scholar

26. Younossi Z, Page S, Rafiq N et al. A biomarker panel for nonalcoholic steatohepatitis (NASH) and NASHrelated fibrosis.Obes Surg 2011; 21: 431–9.10.1007/s11695-010-0204-120532833Open DOISearch in Google Scholar

27. Verderese JP, Younossi Z. Interaction of type 2 diabetes and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2013; 7: 405-7.10.1586/17474124.2013.81104723899279Search in Google Scholar

28. Hamaguchi M, Kojima T, Tekeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.10.7326/0003-4819-143-10-200511150-0000916287793Search in Google Scholar

29. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147–52.10.1172/JCI200422422Search in Google Scholar

30. Kotronen A, Yki-Jarvinen H. Fatty liver. A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27–38.10.1161/ATVBAHA.107.14753817690317Open DOISearch in Google Scholar